Financial StabilityVyome emerges as a pure-play biotech with a clean balance sheet, no debt or warrants, and ~$7M in cash, which is expected to provide runway into 2027.
Pipeline DevelopmentThe ongoing P2 study for VT1953 has demonstrated meaningful improvements in symptom control and a positive safety profile.
Regulatory ProspectsThe company plans to meet with the FDA to discuss a potential pivotal trial if top-line data from the P2 study is positive.